India’s drug regulator has launched a crackdown on high-risk pharmaceutical facilities, taking enforcement action against about 90% of inspected sites.
Quality Control Under Fire
For months, the global industry has been scrutinizing Indian pharmaceuticals following a series of tragic incidents, including child deaths linked to contaminated medicines. In response, India’s Central Drugs Standard Control Organisation (CDSCO) has been conducting a nationwide quality audit, inspecting over 960 facilities since late last year.
CDSCO’s Director-General, Sunil Khurana, revealed that the regulator has taken action against about 90% of these high-risk sites, indicating a significant step towards improving quality control in the industry.
Inspections Underway, Enforcement Actions Taken
The nationwide quality drive was prompted by the increasing concerns over Indian pharmaceuticals, which have been exported to countries worldwide. Inspectors have been scrutinizing manufacturing sites for compliance with quality standards, Good Manufacturing Practices (GMP), and other regulations.
Out of the 960 inspected facilities, CDSCO has identified over 870 sites as high-risk, with the majority facing enforcement actions, including but not limited to, license suspension, revocation, or modification, pending the rectification of non-compliance issues.
What this means
The CDSCO’s actions demonstrate a willingness to hold pharmaceutical manufacturers accountable for adhering to quality standards, which should boost confidence in Indian-made medicines globally. This move will likely reassure consumers, pharmacists, and regulatory bodies worldwide that the Indian pharmaceutical industry is committed to quality and safety.
While this is a notable step forward, the industry and regulator still have much work to do to regain full trust. The CDSCO’s continued efforts to enhance quality control, coupled with increased transparency, will be crucial in re-establishing the reputation of Indian pharmaceuticals on the global stage.
